Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second-line durvalumab + tremelimumab versus platinum-based chemotherapy in advanced non-small cell lung cancer after prior checkpoint inhibitor therapy
2017-003780-35Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Dec 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Progression-free survival 1. Started Dec 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-003780-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003780-35.